Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hypoxia-Inducible Factor 2 Alpha (HIF2α) Inhibitors: Targeting Genetically Driven Tumor Hypoxia

27 Oct 2022

Abstract excerpt

Tumors driven by deficiency of the VHL gene product, which is involved in degradation of the hypoxia-inducible factor subunit 2 alpha (HIF2α), are natural candidates for targeted inhibition of this pathway. Belzutifan, a highly specific and well-tolerated HIF2α inhibitor, recently received FDA approval for the treatment of nonmetastatic renal cell carcinomas, pancreatic neuroendocrine tumors, and central nervous...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer, Hypoxia, and Metabolism
Share to Neuroblastoma Research and Treatments
Share to RNA modifications and cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36301191
DOI: 10.1210/endrev/bnac025

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hypoxia-Inducible Factor 2 Alpha (HIF2α) Inhibitors: Targeting Genetically Driven Tumor HypoxiaPMID 36301191Read ↗

Hypoxia-Inducible Factor in Renal Cell Carcinoma: From Molecular Insights to Targeted TherapiesSemantic proximity Read ↗

New HIF2α inhibitors: potential implications as therapeutics for advanced pheochromocytomas and paragangliomasSemantic proximity Read ↗

Development of drugs targeting hypoxia-inducible factor against tumor cells with VHL mutation: Story of 127 years.Semantic proximity Read ↗

Hypoxia-inducible transcription factors: architects of tumorigenesis and targets for anticancer drug discoverySemantic proximity Read ↗

Von Hippel–Lindau Disease: Molecular Pathological Basis, Clinical Criteria, Genetic Testing, Clinical Features of Tumors and TreatmentSemantic proximity Read ↗

Recent advances in etiology and treatment of von Hippel-Lindau Disease (VHLD).Semantic proximity Read ↗

The VHL tumor suppressor: master regulator of HIF.Semantic proximity Read ↗

Investigating hypoxia-inducible factor signaling in cancer: Mechanisms, clinical implications, targeted therapeutic strategies, and resistanceSemantic proximity Read ↗

Prevalence and prognosis of hypoxia-inducible factor-2α (HIF-2α) pathway gene mutations across advanced solid tumors.Semantic proximity Read ↗

Hypoxia-Inducible Factor 2-Dependent Pathways Driving Von Hippel–Lindau-Deficient Renal CancerSemantic proximity Read ↗

The VHL/HIF Axis in the Development and Treatment of Pheochromocytoma/ParagangliomaSemantic proximity Read ↗

The VHL tumor suppressor and HIF: insights from genetic studies in mice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.